12:00 AM
 | 
Mar 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

OMS302: Phase III data

A double-blind, U.S. Phase III trial in 405 patients showed that OMS302 added to standard irrigation solution used during ophthalmological procedures met the primary endpoint of superior maintenance of intraoperative pupil dilation vs. placebo added to standard irrigation solution (p<0.00001). OMS302 also met the secondary endpoint of reducing pain in the early post-operative period...

Read the full 249 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >